regardless of encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from pharmacy benefit managers. The insurers are typically erecting obstacles to access, such as steep cost requirement